<DOC>
	<DOCNO>NCT00473616</DOCNO>
	<brief_summary>This open-label , multi-center , dose-escalation safety expansion , Phase I study evaluate safety , tolerability , pharmacokinectics investigate biomarker change AZD7762 administer single intravenous unit combination irinotecan . The study sponsor AstraZeneca .</brief_summary>
	<brief_title>Phase I Single Ascending Dose/Multiple Ascending Dose Patients Treated With AZD7762 Irinotecan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Advanced solid tumor standard treatment n't exist longer effective . Must suitable treatment irinotecan Relatively good overall health cancer Poor bone marrow function ( produce enough blood cell ) Serious heart condition Poor liver kidney function Any prior anthracycline treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>solid tumor</keyword>
	<keyword>solid malignancy</keyword>
	<keyword>cancer Eligibility</keyword>
</DOC>